RPS6KB1 and lung cancer: Thioridazine (10 μM) and gefitinib (10 μM) alone (24 hours) did not affect expression of either p-Akt or p-p70S6K in lung cancer cells; but together, they reduced levels of these activated signaling pathways (Fig 4D).